Related Experiment Video

Updated: Nov 24, 2025

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

877

LncRNAs in cancer: Regulatory and therapeutic implications

Arun Nandwani1, Shalu Rathore1, Malabika Datta1

  • 1CSIR-Institute of Genomics and Integrative Biology, Mall Road, Delhi, India and Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, Uttar Pradesh, India.

Cancer Letters
|December 28, 2020
PubMed

Insights

Long noncoding RNAs (lncRNAs) are key regulators of cell function, implicated in various diseases. Their aberrant signatures in cancer highlight their potential as therapeutic targets.

Area of Science:

  • Molecular Biology
  • Genomics
  • RNA Biology

Background:

  • Long noncoding RNAs (lncRNAs) are RNA molecules longer than 200 nucleotides that do not code for proteins.
  • lncRNAs play critical roles in regulating diverse cellular processes and maintaining cell function.
  • Emerging evidence implicates lncRNAs in a growing range of diseases, including cancer.

Purpose of the Study:

  • To review the current understanding of lncRNAs.
  • To explore the implications of lncRNAs in various types of cancer.
  • To discuss the potential therapeutic utility of lncRNAs.

Main Methods:

  • Literature review and synthesis of current research on lncRNAs.
  • Analysis of functional pathways involving lncRNAs (e.g., chromatin, protein, RNA interactions).
  • Examination of aberrant lncRNA signatures in cancer.

Main Results:

  • lncRNAs represent a significant layer of biological regulation.
  • Aberrant lncRNA expression is a consistent feature across most cancer types.
  • lncRNAs modulate key cellular processes such as proliferation, migration, differentiation, and apoptosis.

Conclusions:

  • lncRNAs are crucial in cellular function and disease pathogenesis.
  • Dysregulated lncRNAs in cancer present opportunities for diagnostic and therapeutic strategies.
  • Further research into lncRNA mechanisms could unlock novel treatment avenues for cancer.
Keywords:
BiomarkerCancerTherapylncRNAs

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.8K

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.4K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

3.1K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.1K
Regulation of Expression at Multiple Steps01:23

Regulation of Expression at Multiple Steps

The gene expression in cells is regulated at different stages: (i) transcription, (ii) RNA processing, (iii) RNA localization, and (iv) translation. Transcriptional regulation is mediated by regulatory proteins such as transcription factors, activators, or repressors—these control gene expression by initiating or inhibiting the transcription of genes. Once a precursor or pre-mRNA is produced, it undergoes post-transcriptional modification, including 5' capping, splicing, and the...
1.2K